MPOS Stock Overview
Micropos Medical AB (publ), a medical device company, develops technologies that enhance the precision in radiotherapy of cancer.
Micropos Medical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr2.88|
|52 Week High||kr3.99|
|52 Week Low||kr1.92|
|1 Month Change||-5.88%|
|3 Month Change||2.86%|
|1 Year Change||7.06%|
|3 Year Change||234.88%|
|5 Year Change||63.64%|
|Change since IPO||-63.31%|
Recent News & Updates
We're Not Very Worried About Micropos Medical's (NGM:MPOS) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|MPOS||SE Medical Equipment||SE Market|
Return vs Industry: MPOS exceeded the Swedish Medical Equipment industry which returned -35% over the past year.
Return vs Market: MPOS exceeded the Swedish Market which returned -23.6% over the past year.
|MPOS Average Weekly Movement||9.0%|
|Medical Equipment Industry Average Movement||8.5%|
|Market Average Movement||7.4%|
|10% most volatile stocks in SE Market||12.2%|
|10% least volatile stocks in SE Market||4.7%|
Stable Share Price: MPOS is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: MPOS's weekly volatility (9%) has been stable over the past year.
About the Company
Micropos Medical AB (publ), a medical device company, develops technologies that enhance the precision in radiotherapy of cancer. Its products include RayPilot receiving system, a sensor plate; RayPilot transmitter for positioning, patient identification, and in situ dosimetry; and RayPilot software for use in patient identification, patient set up, ROI positioning, and in situ dosimetry in the control room. Micropos Medical AB (publ) was founded in 2003 and is based in Gothenburg, Sweden.
Micropos Medical Fundamentals Summary
|MPOS fundamental statistics|
Is MPOS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MPOS income statement (TTM)|
|Cost of Revenue||kr922.00k|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.12|
|Net Profit Margin||-589.18%|
How did MPOS perform over the long term?See historical performance and comparison
Is MPOS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MPOS?
Other financial metrics that can be useful for relative valuation.
|What is MPOS's n/a Ratio?|
Price to Book Ratio vs Peers
How does MPOS's PB Ratio compare to its peers?
|MPOS PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
Price-To-Book vs Peers: MPOS is expensive based on its Price-To-Book Ratio (18x) compared to the peer average (7.2x).
Price to Earnings Ratio vs Industry
How does MPOS's PE Ratio compare vs other companies in the SE Medical Equipment Industry?
Price-To-Book vs Industry: MPOS is expensive based on its Price-To-Book Ratio (18x) compared to the Swedish Medical Equipment industry average (3.6x)
Price to Book Ratio vs Fair Ratio
What is MPOS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||18x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate MPOS's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of MPOS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate MPOS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MPOS's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MPOS's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Micropos Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Micropos Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Micropos Medical's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
How has Micropos Medical performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MPOS is currently unprofitable.
Growing Profit Margin: MPOS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MPOS is unprofitable, but has reduced losses over the past 5 years at a rate of 3.4% per year.
Accelerating Growth: Unable to compare MPOS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MPOS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (6.3%).
Return on Equity
High ROE: MPOS has a negative Return on Equity (-78.03%), as it is currently unprofitable.
Discover strong past performing companies
How is Micropos Medical's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MPOS's short term assets (SEK21.0M) exceed its short term liabilities (SEK6.2M).
Long Term Liabilities: MPOS's short term assets (SEK21.0M) exceed its long term liabilities (SEK930.0K).
Debt to Equity History and Analysis
Debt Level: MPOS has more cash than its total debt.
Reducing Debt: MPOS's debt to equity ratio has reduced from 3% to 2.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MPOS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MPOS has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 2.8% each year.
Discover healthy companies
What is Micropos Medical current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MPOS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MPOS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MPOS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MPOS's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MPOS has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Thomas Lindstrom (55 yo)
Mr. Thomas Lindstrom has been Chief Executive Officer at Micropos Medical AB (publ) since June 2020. He has a long background in Sales, marketing and organisation development within Medtech industry since...
CEO Compensation Analysis
Compensation vs Market: Thomas's total compensation ($USD103.38K) is below average for companies of similar size in the Swedish market ($USD233.45K).
Compensation vs Earnings: Insufficient data to compare Thomas's compensation with company performance.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.6%.
Micropos Medical AB (publ)'s employee growth, exchange listings and data sources
- Name: Micropos Medical AB (publ)
- Ticker: MPOS
- Exchange: NGM
- Founded: 2003
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: kr358.275m
- Shares outstanding: 124.40m
- Website: https://www.micropos.se
Number of Employees
- Micropos Medical AB (publ)
- Adolf Edelsvärds gata 11
- Västra Götaland County
- 414 51
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.